Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.
about
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioTumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cellsA phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantationHistology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cellsPD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array TestingEfficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation.Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survivalIpilimumab for Patients with Relapse after Allogeneic Transplantation.Transplantation for myelodysplastic syndromes 2013.Relapse after allogeneic stem cell transplantationMajor Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.Emerging cell cycle inhibitors for acute myeloid leukemia.Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromesOutcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies.Immunotherapy following relapse of acute leukaemia after T-cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease.Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.Relapse post hematopoietic SCT remains the Achilles heel for the field.Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study
P2860
Q33391089-33D68446-5633-4E5B-97F0-CA7736D91E13Q34202277-1C2F8B12-97B6-4C6A-BEE3-AC78823C7E81Q34288677-E35ECDBC-AA85-4E59-9914-C67673D12C92Q34355686-5BFD6C4D-6AB4-4CF6-AF74-A3160ECAACABQ35068749-FBDF532F-770A-4AEA-8913-129C6FD25021Q35223780-AF03E48A-A541-45BD-8E48-BF1CA806F98DQ35651760-07436F7A-D181-4667-B96B-4D05E7304C53Q35921900-0BAF715F-DADD-47AD-940A-965644FB0B0BQ36055095-6E783228-0F48-474A-B84F-B2917505BEB0Q36635154-868D3F52-F73B-4DCA-A81A-DE97EFAFF326Q36708930-86E576A4-5FAF-46E8-929D-7C5B0BA8B95BQ36919619-6ECA138E-6616-49E1-BBD4-F6779339AA8AQ36961764-FAB6701D-E1AE-4471-AB73-238B04A4C1DDQ37491836-E84B5D06-F71F-4874-9C47-86E5FCC0DB9AQ37600407-73DE23EB-5A03-4320-83F3-6B6188C285EEQ37810125-410B5531-242D-4A0F-9EF1-0C394485696DQ38654516-32BC3B71-AC6D-4B7B-84EE-6397E9EADDBAQ38785380-87536FF0-0718-419B-988A-0E72CAFD202AQ38852431-EF5649C3-CAEE-4B53-8F25-828707E8CEAFQ40466623-C034B77A-643C-47D6-81B0-B49D23EF6B39Q40542266-9EBAE1D3-D8CE-474D-87F8-00F3C12E44E1Q41564670-A3A99E27-1D36-48AA-823F-0FD0173D42DEQ42344562-4A6457F3-817C-460F-ABDE-6CE13EEA6E76Q43917590-84F0F531-7A7B-4F7C-BE23-5C657F4D3326Q44325600-6FC01ADC-8157-4F29-BB96-EFFAC5CE7167Q47144269-2FAEB237-2403-4C07-BC81-DEF0775B091DQ47741553-74728B3B-F073-448B-8A38-C31B67EFE845Q48025011-66FA2A36-E420-42E3-A485-505C3E1CAD06Q52728106-A535D0F8-940F-4DB2-B93C-9E3B022F1F95Q52848310-D67C8D8A-B0C8-4467-BEA1-621B8726FB77Q52981533-73497875-1483-410A-A3B4-13A44A33513BQ53029398-B94E0FB2-8A22-44F6-B167-B79CAF6407ECQ58706086-86636BD6-51BD-4A29-9D98-6C913D179A8D
P2860
Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Outcomes among patients with r ...... opoietic cell transplantation.
@en
Outcomes among patients with r ...... opoietic cell transplantation.
@nl
type
label
Outcomes among patients with r ...... opoietic cell transplantation.
@en
Outcomes among patients with r ...... opoietic cell transplantation.
@nl
prefLabel
Outcomes among patients with r ...... opoietic cell transplantation.
@en
Outcomes among patients with r ...... opoietic cell transplantation.
@nl
P50
P1476
Outcomes among patients with r ...... opoietic cell transplantation.
@en
P2093
Mary E D Flowers
Paul J Martin
P304
P356
10.1016/J.BBMT.2007.06.007
P577
2007-08-03T00:00:00Z